Kala Bio, Inc. (KALA)
0.57
+0.03
(+5.97%)
USD |
NASDAQ |
Sep 09, 13:39
Kala Bio Shareholders Equity (Quarterly) : 9.044M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 9.044M |
| March 31, 2026 | 10.76M |
| December 31, 2025 | 6.996M |
| September 30, 2025 | -8.665M |
| June 30, 2025 | -3.206M |
| March 31, 2025 | 5.708M |
| December 31, 2024 | 12.33M |
| September 30, 2024 | 6.859M |
| June 30, 2024 | 13.72M |
| March 31, 2024 | 6.661M |
| December 31, 2023 | 7.504M |
| September 30, 2023 | 11.22M |
| June 30, 2023 | 17.49M |
| March 31, 2023 | 23.46M |
| December 31, 2022 | 18.97M |
| September 30, 2022 | -0.968M |
| June 30, 2022 | -31.55M |
| March 31, 2022 | -5.284M |
| December 31, 2021 | 16.80M |
| September 30, 2021 | 61.47M |
| June 30, 2021 | 84.27M |
| March 31, 2021 | 109.79M |
| December 31, 2020 | 100.00M |
| September 30, 2020 | 106.03M |
| Date | Value |
|---|---|
| June 30, 2020 | 128.94M |
| March 31, 2020 | 141.51M |
| December 31, 2019 | 29.69M |
| September 30, 2019 | 43.06M |
| June 30, 2019 | 61.07M |
| March 31, 2019 | 82.37M |
| December 31, 2018 | 104.98M |
| September 30, 2018 | 54.93M |
| June 30, 2018 | 68.09M |
| March 31, 2018 | 80.27M |
| December 31, 2017 | 89.68M |
| September 30, 2017 | 98.86M |
| June 30, 2017 | 10.97M |
| March 31, 2017 | 21.39M |
| December 31, 2016 | |
| September 30, 2016 | |
| June 30, 2016 | |
| March 31, 2016 | |
| December 31, 2015 | -5.793M |
| September 30, 2015 | -1.209M |
| June 30, 2015 | |
| March 31, 2015 | |
| December 31, 2014 | 3.262M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 1.307B |
| Alnylam Pharmaceuticals, Inc. | 1.354B |
| Anika Therapeutics, Inc. | 137.28M |
| Savara, Inc. | 143.66M |
| Vericel Corp. | 370.04M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 10.58M |
| Total Liabilities (Quarterly) | 1.538M |
| Current Ratio | 6.880 |
| Net Debt Paydown Yield | 19.34% |